Sanofi $SNY Stock Position Raised by NewSquare Capital LLC

NewSquare Capital LLC lifted its stake in shares of Sanofi (NASDAQ:SNY) by 5.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 116,355 shares of the company’s stock after acquiring an additional 5,641 shares during the quarter. NewSquare Capital LLC’s holdings in Sanofi were worth $5,556,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nuveen LLC purchased a new stake in shares of Sanofi during the first quarter worth $177,831,000. Federated Hermes Inc. raised its holdings in shares of Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after acquiring an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC bought a new position in shares of Sanofi in the first quarter worth about $48,938,000. Regal Partners Ltd raised its holdings in Sanofi by 102.3% in the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock valued at $74,794,000 after acquiring an additional 782,838 shares in the last quarter. Finally, Raymond James Financial Inc. raised its holdings in Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after acquiring an additional 425,597 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Trading Down 1.0%

Shares of SNY stock opened at $50.05 on Tuesday. The firm has a 50 day moving average price of $48.69 and a two-hundred day moving average price of $49.53. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $122.90 billion, a PE ratio of 11.72, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The firm had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period last year, the business posted $2.25 earnings per share. The business’s revenue for the quarter was down 7.5% compared to the same quarter last year. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.